Beta-2-microglobulin amyloidosis in long-term dialysis patients

American Journal of Nephrology

Volumn 9, Issue 3, 1989, Pages 177-183

  Stone, William J ^a   Hakim, Raymond M ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Amyloidosis; Arthropathy; Carpal tunnel syndrome; Hemodialysis; Osteodystrophy; 2< inf> Microglobulin

Indexed keywords

BETA 2 MICROGLOBULIN;

AMYLOIDOSIS; ARTHROPATHY; CARPAL TUNNEL SYNDROME; EDITORIAL; HEMODIALYSIS; HISTOLOGY; HUMAN; OSTEODYSTROPHY;

AMYLOIDOSIS; BETA 2-MICROGLOBULIN; BIOLOGICAL FACTORS; CARPAL TUNNEL SYNDROME; CYTOKINES; FRACTURES, SPONTANEOUS; HUMAN; JOINT DISEASES; RENAL DIALYSIS; SUPPORT, U.S. GOV'T, NON-P.H.S.;

EID: 0024370023     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000167962     Document Type: Editorial

References (59)

1. Gorevic PD, Casey TT, Stone WJ, et al: Beta-2-microglobulin is an amyloidogenic protein in man. J Clin Invest 1985;76:2425-2429.
2. Gejyo F, Yamada T, Odani S, et al: A new form of amyloid protein associated with chronic hemodialysis was identified as β2-microglobulin. Biochem Biophys Res Commun 1985; 129: 701-706.
3. Bardin T, Kuntz D, Zingraff J, et al: Synovial amyloidosis in patients undergoing long-term hemodialysis. Arthritis Rheum 1985;28:1052-1058.
4. Van Ypersele de Strihou C, Honhon B, Vandenbroucke JM, et al: Dialysis amyloidosis. Adv Nephrol 1988;17:401-422.
5. Warren DJ, Otieno LS: Carpal tunnel syndrome in patients on intermittent hemodialysis. Postgrad Med J 1975;51:450-452.
6. Laurent G. Calemard E. Charra B: Dialysis-related amyloidosis. Kidney Int 1988;33 (suppl 24):32-34.
7. Teitz CC, DeLisa JA, Halter SK: Results of carpal tunnel release in renal hemodialysis patients. Clin Orthop 1985; 198:197-200.
8. Bradish CF: Carpal tunnel syndrome in patients on haemodial-ysis. J Bone Joint Surg (Br) 1985;67-B: 130-132.
9. Fenves AZ, Emmett M, White MG, et al: Carpal tunnel syndrome with cystic bone lesions secondary to amyloidosis in chronic hemodialysis patients. Am J Kidney Dis 1986;7:130-134.
10. Spertini F, Wauters JP, Poulenas I: Carpal tunnel syndrome: a frequent, invalidating, long-term complication of chronic hemodialysis. Clin Nephrol 1984;21:98-101.
11. Delmez JA, Holtmann B, Sicard GA, et al: Peripheral nerve entrapment syndromes in chronic hemodialysis patients. Nephron 1982;30:118-123.
12. Boutcillcr G, Ton That H, Goudablc C. et al: Amyloidosis in chronic hemodialysis: rheumatological aspects. Contrib Nephrol 1988;62:67-74.
13. Vandenbroucke JM, Huaux J-P, Noel H, et al: Capsulo-synovial and bone amyloidosis: biocompatibility phenomenon of hemodialysis? Kidney Int 1988;33 (suppl 24):35-36.
14. Munoz-Gomez J, Bergada-Barado E, Gomez-Perez R, et al: Amyloid arthropathy in patients undergoing periodical hemodialysis for chronic renal failure: a new complication. Ann Rheum Dis 1985;44:729-733.
15. Nakazawa R, Hamaguchi K, Hosaka E. et al: Synovial amyloidosis of β2-microglobulin type in patients undergoing long-term hemodialysis. Nephron 1987;44:379-380.
16. DiRaimondo CR, Casey TT, DiRaimondo CV, et al: Pathologic fractures associated with idiopathic amyloidosis of bone in chronic hemodialysis patients. Nephron 1986;43:22-27.
17. Bardin T, Zingraff J, Shirahama T, et al: Hemodialysis-associated amyloidosis and beta-2-microglobulin. Clinical and immunohistochemical study. Am J Med 1987;83:419-424.
18. Casey TT, Stone WJ, DiRaimondo CR, et al: Tumoral amyloidosis of beta-2-microglobulin origin in association with long-term hemodialysis. Hum Pathol 1986;17:731-738.
19. Morita T, Suzuki M, Kamimura A, et al: Amyloidosis of possible new type in patients receiving long-term hemodialysis. Arch Pathol Lab Med 1985;109:1029-1032.
20. Takahashi S, Morita T, Koda Y, et al: Gastrointestinal involvement of dialysis-related amyloidosis. Clin Nephrol 1988;30: 168-171.
21. Campistol JM, Cases A, Torras A, et al: Visceral involvement of dialysis amyloidosis. Am J Nephrol 1987;7:390-393.
22. Ogawa H, Saito A, Hirabayashi N, et al: Amyloid deposition in systemic organs in long-term hemodialysis patients. Clin Nephrol 1987;28:199-204.
23. Theaker JM, Raine AEG, Rainey AJ, et al: Systemic amyloidosis of β2-microglobulin type: a complication of long-term haemodi-alysis. J Clin Pathol 1987;40:1247-1251.
24. Linke RP, Bommer J, Ritz E, et al: Amyloid kidney stones of uremic patients consist of beta-2-microglobulin fragments. Biochem Biophys Res Commun 1987;136:665-671.
25. Reese W, Hopkovitz A, Lifschitz MD: ß2-Microglobulin and associated amyloidosis presenting as bilateral popliteal tumors. Am J Kidney Dis 1988;12:323-325.
26. Noel LH, Zingraff J, Bardin T, et al: Tissue distribution of dialysis amyloidosis. Clin Nephrol 1987;27:175-178.
27. Varga J, Idelson BA, Felson D, et al: Lack of amyloid in abdominal fat aspirates from patients undergoing long-term hemodialysis. Arch Intern Med 1987;147:1455-1457.
28. Naidich JB, Mossey RT, McHeffey-Atkinson B, et al: Spondyloarthropathy from long-term hemodialysis. Radiology 1988; 167:761-764.
29. Grateau G, Zingraff J, Fauchet M, et al: Radionuclide exploration of dialysis amyloidosis: preliminary experience. Am J Kidney Dis 1988;11:231-237.
30. Bommer J, Seelig P, Seelig R, et al: Determinants of plasma ß2-microglobulin concentration: possible relation to membrane biocompatibility. Nephrol Dial Transplant 1987;2:22-25.
31. Gejyo F, Homma N, Suzuki Y, et al: Serum levels of ß2-micro-globulin as a new form of amyloid protein in patients undergoing long-term hemodialysis (letter). N Engl J Med 1986;314:585-586.
32. Rcvillard JP, Vincent C: Structure and metabolism of beta-2-microglobulin. Contrib Nephrol 1988:62:44-53.
33. Schardijn GHC, Statius van Eps LW: ß2-Microglobulin: its significance in the evaluation of renal function. Kidney Int 1987; 32:635-641.
34. Brown PH, Kalra PA, Turney JH, et al: Serum low-molecular-weight proteins in haemodialysis patients: effect of residual renal function. Nephrol Dial Transplant 1988;3:169-163.
35. Mayer G, Thum J, Woloszczuk W, et al: Beta-2-microglobulin in hemodialysis patients. Effects of different dialyzers and different dialysis procedures. Am J Nephrol 1988;8:280-284.
36. Zingraff J, Beync P, Urena P, et al: Influence of haemodialysis membranes on ß2-microglobulin kinetics: in vivo and in vitro studies. Nephrol Dial Transplant 1988;3:284-290.
37. Tielemans C, Dratwa M, Bergmann P, et al: Continuous ambulatory peritoneal dialysis versus haemodialysis: a lesser risk of amyloidosis? Nephrol Dial Transplant 1988;3:291-294.
38. Kaiser JP, Hagemann J, von Herrath D, et al: Different handling of beta-2-microglobulin during hemodialysis and hémofiltration. Nephron 1988;48:132-135.
39. Floge J, Granolleras C, Bingel M, et al: ß2-microglobulin kinetics during haemodialysis and haemofiltration. Nephrol Dial Transplant 1987;1:223-228.
40. Drueke T, Zingraff J: Beta-2-microglobulin-related amyloidosis in long-term hemodialysis patients: possible pathogenetic mechanisms. Contrib Nephrol 1987;59:99-109.
41. Ogawa H, Saito A, Oda O, et al: Detection of novel ß2-micro-globulin in the serum of hemodialysis patients and its amyloido-genic predisposition. Clin Nephrol 1988;30:158-163.
42. Wahner HW, Kyle RA, Beabout JW: Scintigraphic evaluation of the skeleton in multiple myeloma. Mayo Clinic Proc 1980;55: 739-746.
43. Garrett IR, Durie BGM, Nedwin GE, et al: Production of lym-photoxin, a bone-resorbing cytokine, by cultured human myeloma cells. N Engl J Med 1987;317:526-532.
44. Mundy GR: Hypercalcemia of malignancy revisited. J Clin Invest 1988;82:1-6.
45. Ziegler EJ: Tumor necrosis factor in humans. N Engl J Med 1988;318:1533-1535.
46. Betz M, Haensch G-M, Rauterberg E-W, et al: Cuprammonium membranes stimulate interleukin-1 release and arachidonic acid metabolism in monocytes in the absence of complement. Kidney Int 1988:34:67-73.
47. Amato M, Cozzolino F, Bergesio F. et al: In vitro interleukin-1 production by different dialysis membranes. Nephrol Dial Transplant 1988;3:432-434.
48. Lonneman G, van der Meer JWM, Endres S. et al: Induction and removal of tumor necrosis factor (TNF) and interleukin-1 (IL-1) during in vitro hemodialysis (HD) (abstract). Kidney Int 1988; 33:229.
49. Canalis E., McCarthy T., Centrella M.: Growth factors and the regulation of bone remodeling. J Clin Invest 1988:81:277-281.
50. Jorstad S, Smeby LC, Balstad T, et al: Removal, generation and adsorption of beta-2-microglobulin during hémofiltration with five different membranes. Blood Purif 1988;6:96-105.
51. Vandenbroucke JM, Jadoul M, Maldaguc B, et al: Possible role of dialysis membrane characteristics in amyloid osteoarthropathy (letter). Lancet 1986;i: 1210-1211.
52. Chanard J, Rindi P, Maheut H. et al: Low prevalence of carpal tunnel syndrome in patients hemodialyzed with high-flux membrane (abstract). Nephrol Dial Transplant 1988:3:551.
53. Rockel A, Hertel J, Fiegel P, et al: Permeability and secondary membrane formation of a high-flux polysulfone hemofilter. Kidney Int 1986;30:429-432.
54. Blumberg A, Burgi W: Behavior of β2-microglobulin in patients with chronic renal failure undergoing hemodialysis, hémodiafiltration and continuous ambulatory peritoneal dialysis (CAPD). Clin Nephrol 1987;27:245-249.
55. Brancaccio D, Anelli A, Barbesti S, et al: Labelled beta-2-micro-globulin (β2m) removal using hemoperfusion, conventional and high-flux dialysis membranes (abstract). Kidney Int 1988;33: 217.
56. Gagnon RF, Somerville P, Kaye M: β2-Microglobulin serum levels in patients on long-term dialysis. Periton Dial Bull 1987;7: 29-31.
57. DiRaimondo CR, McCarley P, Stone WJ: Beta-2-microglobulin in peritoneal dialysis patients: serum levels and peritoneal clearances. Periton Dial Int 1988;8:43-47.
58. Benz RL, Siegfried JW, Teehan BP: Carpal tunnel syndrome in dialysis patients: comparison between continuous ambulatory peritoneal dialysis and hemodialysis populations. Am J Kidney Dis 1988;11:473-476.
59. Floege J, Granolleras C, Koch KM, et al: Which membrane? Should beta-2-microglobulin decide on the choice of today’s hemodialysis membrane? Nephron 1988;50:177-181.